|
1
|
Nilsson B, Bümming P, Meis-Kindblom JM,
Odén A, Dortok A, Gustavsson B, Sablinska K and Kindblom LG:
Gastrointestinal stromal tumors: The incidence, prevalence,
clinical course, and prognostication in the preimatinib mesylate
era-a population-based study in western Sweden. Cancer.
103:821–829. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Corless CL, Fletcher JA and Heinrich MC:
Biology of gastrointestinal stromal tumors. J Clin Oncol.
22:3813–3825. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Corless CL, Barnett CM and Heinrich MC:
Gastrointestinal stromal tumours: Origin and molecular oncology.
Nat Rev Cancer. 11:865–878. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heinrich MC, Corless CL, Demetri GD,
Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den
Abbeele AD, Druker BJ, et al: Kinase mutations and imatinib
response in patients with metastatic gastrointestinal stromal
tumor. J Clin Oncol. 21:4342–4349. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Casali PG, Zalcberg J, Le Cesne A,
Reichardt P, Blay JY, Lindner LH, Judson IR, Schöffski P, Leyvraz
S, Italiano A, et al: Ten-year progression-free and overall
survival in patients with unresectable or metastatic GI stromal
tumors: Long-term analysis of the European organisation for
research and treatment of cancer, Italian sarcoma group, and
australasian gastrointestinal trials group intergroup phase III
randomized trial on imatinib at two dose levels. J Clin Oncol.
35:1713–1720. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blanke CD, Demetri GD, von Mehren M,
Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD,
Roberts PJ, Heinz D, et al: Long-term results from a randomized
phase II trial of standard-versus higher-dose imatinib mesylate for
patients with unresectable or metastatic gastrointestinal stromal
tumors expressing KIT. J Clin Oncol. 26:620–625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heinrich MC, Rankin C, Blanke CD, Demetri
GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA,
Tap WD, et al: Correlation of long-term results of imatinib in
advanced gastrointestinal stromal tumors with next-generation
sequencing results: Analysis of phase 3 SWOG intergroup trial
S0033. JAMA Oncol. 3:944–952. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nannini M, Biasco G, Astolfi A and
Pantaleo MA: An overview on molecular biology of KIT/PDGFRA wild
type (WT) gastrointestinal stromal tumours (GIST). J Med Genet.
50:653–661. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Szucs Z, Thway K, Fisher C, Bulusu R,
Constantinidou A, Benson C, van der Graaf WT and Jones RL:
Molecular subtypes of gastrointestinal stromal tumors and their
prognostic and therapeutic implications. Future Oncol. 13:93–107.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mei L, Smith SC, Faber AC, Trent J,
Grossman SR, Stratakis CA and Boikos SA: Gastrointestinal stromal
tumors: The GIST of precision medicine. Trends Cancer. 4:74–91.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pantaleo MA, Astolfi A, Urbini M, Nannini
M, Paterini P, Indio V, Saponara M, Formica S, Ceccarelli C,
Casadio R, et al: Analysis of all subunits, SDHA, SDHB, SDHC, SDHD,
of the succinate dehydrogenase complex in KIT/PDGFRA wild-type
GIST. Eur J Hum Genet. 22:32–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Janeway KA, Kim SY, Lodish M, Nosé V,
Rustin P, Gaal J, Dahia PL, Liegl B, Ball ER, Raygada M, et al:
Defects in succinate dehydrogenase in gastrointestinal stromal
tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA.
108:314–318. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pantaleo MA, Nannini M, Corless CL and
Heinrich MC: Quadruple wild-type (WT) GIST: Defining the subset of
GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling
pathways. Cancer Med. 4:101–103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Daniels M, Lurkin I, Pauli R, Erbstösser
E, Hildebrandt U, Hellwig K, Zschille U, Lüders P, Krüger G, Knolle
J, et al: Spectrum of KIT/PDGFRA/BRAF mutations and
phosphatidylinositol-3-kinase pathway gene alterations in
gastrointestinal stromal tumors (GIST). Cancer Lett. 312:43–54.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shin HT, Choi YL, Yun JW, Kim NKD, Kim SY,
Jeon HJ, Nam JY, Lee C, Ryu D, Kim SC, et al: Prevalence and
detection of low-allele-fraction variants in clinical cancer
samples. Nat Commun. 8:13772017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brenca M, Rossi S, Polano M, Gasparotto D,
Zanatta L, Racanelli D, Valori L, Lamon S, Dei Tos AP and Maestro
R: Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion
involved in GIST. J Pathol. 238:543–549. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pantaleo MA, Urbini M, Indio V, Ravegnini
G, Nannini M, De Luca M, Tarantino G, Angelini S, Gronchi A,
Vincenzi B, et al: Genome-wide analysis identifies MEN1 and MAX
mutations and a neuroendocrine-like molecular heterogeneity in
quadruple WT GIST. Mol Cancer Res. 15:553–562. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Heinrich MC, Owzar K, Corless CL, Hollis
D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin
C, et al: Correlation of kinase genotype and clinical outcome in
the North American intergroup phase III trial of imatinib mesylate
for treatment of advanced gastrointestinal stromal tumor: CALGB
150105 study by cancer and leukemia group B and southwest oncology
group. J Clin Oncol. 26:5360–5367. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bombac A, Zakotnik B, Bucic M, Setrajcic
Dragos V, Gazic B, Stegel V, Klancar G and Novakovic S: Mutational
spectrum and classification of novel mutations in patients with
metastatic gastrointestinal stromal tumours. Int J Oncol.
56:1468–1478. 2020.PubMed/NCBI
|
|
20
|
Klančar G, Blatnik A, Šetrajčič Dragoš V,
Vogrič V, Stegel V, Blatnik O, Drev P, Gazič B, Krajc M and
Novaković S: A novel germline MLH1 in-frame deletion in a slovenian
lynch syndrome family associated with uncommon isolated PMS2 loss
in tumor tissue. Genes (Basel). 11:3252020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
den Dunnen JT, Dalgleish R, Maglott DR,
Hart RK, Greenblatt MS, McGowan-Jordan J, Roux AF, Smith T,
Antonarakis SE and Taschner PE: HGVS recommendations for the
description of sequence variants: 2016 Update. Hum Mutat.
37:564–569. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choi H, Charnsangavej C, Faria SC,
Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA and
Benjamin RS: Correlation of computed tomography and positron
emission tomography in patients with metastatic gastrointestinal
stromal tumor treated at a single institution with imatinib
mesylate: Proposal of new computed tomography response criteria. J
Clin Oncol. 25:1753–1759. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bland JM and Altman DG: Survival
probabilities (the Kaplan-Meier method). BMJ. 317:15721998.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chia PL, Gedye C, Boutros PC,
Wheatley-Price P and John T: Current and evolving methods to
visualize biological data in cancer research. J Natl Cancer Inst.
108:djw0312016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Janeway KA, Liegl B, Harlow A, Le C,
Perez-Atayde A, Kozakewich H, Corless CL, Heinrich MC and Fletcher
JA: Pediatric KIT wild-type and platelet-derived growth factor
receptor alpha-wild-type gastrointestinal stromal tumors share KIT
activation but not mechanisms of genetic progression with adult
gastrointestinal stromal tumors. Cancer Res. 67:9084–9088. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Murray M, Hatcher H, Jessop F, Williams D,
Carroll N, Bulusu R and Judson I: Treatment of wild-type
gastrointestinal stromal tumor (WT-GIST) with imatinib and
sunitinib. Pediatr Blood Cancer. 50:386–388. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Casali PG, Blay JY, Abecassis N, Bajpai J,
Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee
JVMG, et al: Gastrointestinal stromal tumours:
ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 33:20–33. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
et al: Gain-of-function mutations of c-kit in human
gastrointestinal stromal tumors. Science. 279:577–580. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Joensuu H, Wardelmann E, Sihto H, Eriksson
M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S,
Hohenberger P, et al: Effect of KIT and PDGFRA mutations on
survival in patients with gastrointestinal stromal tumors treated
with adjuvant imatinib: An exploratory analysis of a randomized
clinical trial. JAMA Oncol. 3:602–609. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Blanke CD, Rankin C, Demetri GD, Ryan CW,
von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki
RG, et al: Phase III randomized, intergroup trial assessing
imatinib mesylate at two dose levels in patients with unresectable
or metastatic gastrointestinal stromal tumors expressing the kit
receptor tyrosine kinase: S0033. J Clin Oncol. 26:626–632. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Boikos SA, Pappo AS, Killian JK, LaQuaglia
MP, Weldon CB, George S, Trent JC, von Mehren M, Wright JA,
Schiffman JD, et al: Molecular subtypes of KIT/PDGFRA wild-type
gastrointestinal stromal tumors: A report from the national
institutes of health gastrointestinal stromal tumor clinic. JAMA
Oncol. 2:922–928. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wada R, Arai H, Kure S, Peng WX and Naito
Z: ‘Wild type’ GIST: Clinicopathological features and clinical
practice. Pathol Int. 66:431–437. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yoo C, Ryu MH, Jo J, Park I, Ryoo BY and
Kang YK: Efficacy of imatinib in patients with platelet-derived
growth factor receptor alpha-mutated gastrointestinal stromal
tumors. Cancer Res Treat. 48:546–552. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cassier PA, Fumagalli E, Rutkowski P,
Schöffski P, Van Glabbeke M, Debiec-Rychter M, Emile JF, Duffaud F,
Martin-Broto J, Landi B, et al: Outcome of patients with
platelet-derived growth factor receptor alpha-mutated
gastrointestinal stromal tumors in the tyrosine kinase inhibitor
era. Clin Cancer Res. 18:4458–4464. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Corless CL, Schroeder A, Griffith D, Town
A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J and
Heinrich MC: PDGFRA mutations in gastrointestinal stromal tumors:
Frequency, spectrum and in vitro sensitivity to imatinib. J Clin
Oncol. 23:5357–5364. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Farag S, Somaiah N, Choi H, Heeres B, Wang
WL, van Boven H, Nederlof P, Benjamin R, van der Graaf W, Grunhagen
D, et al: Clinical characteristics and treatment outcome in a large
multicentre observational cohort of PDGFRA exon 18 mutated
gastrointestinal stromal tumour patients. Eur J Cancer. 76:76–83.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
National Library of Medicine (NIH), .
ClinVar. NCBI; Bethesda, MD: 2022, https://www.ncbi.nlm.nih.gov/clinvar
|
|
39
|
Cataloque of Somatic Mutations in Cancer
(COSMIC), . COSMIC v96. released 31-May-2022. https://cancer.sanger.ac.uk/cosmic
|
|
40
|
Joensuu H, Roberts PJ, Sarlomo-Rikala M,
Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville
R, Dimitrijevic S, Druker B and Demetri GD: Effect of the tyrosine
kinase inhibitor STI571 in a patient with a metastatic
gastrointestinal stromal tumor. N Engl J Med. 344:1052–1056. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mühlenberg T, Ketzer J, Heinrich MC,
Grunewald S, Marino-Enriquez A, Trautmann M, Hartmann W, Wardelmann
E, Treckmann J, Worm K, et al: KIT-dependent and KIT-independent
genomic heterogeneity of resistance in gastrointestinal stromal
tumors-TORC1/2 inhibition as salvage strategy. Mol Cancer Ther.
18:1985–1996. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Heinrich MC, Corless CL, Blanke CD,
Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M,
Fletcher CD, Sandau K, et al: Molecular correlates of imatinib
resistance in gastrointestinal stromal tumors. J Clin Oncol.
24:4764–4774. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Astolfi A, Indio V, Nannini M, Saponara M,
Schipani A, De Leo A, Altimari A, Vincenzi B, Comandini D, Grignani
G, et al: Targeted deep sequencing uncovers cryptic KIT mutations
in KIT/PDGFRA/SDH/RAS-P wild-type GIST. Front Oncol. 10:5042020.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Daum O, Zalud R, Grossmann P, Mukensnabl P
and Michal M: A case of imatinib-naive ileal fibrous stromal tumor
with unusual morphology and double PDGFRA mutation. Appl
Immunohistochem Mol Morphol. 18:484–485. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ginori A, Scaramuzzino F, Marsili S and
Tripodi S: Late hepatic metastasis from a duodenal gastrointestinal
stromal tumor (29 years after surgery): Report of a case and review
of the literature. Int J Surg Pathol. 23:317–321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nannini M, Astolfi A, Paterini P, Urbini
M, Santini D, Catena F, Indio V, Casadio R, Pinna AD, Biasco G and
Pantaleo MA: Expression of IGF-1 receptor in KIT/PDGF receptor-α
wild-type gastrointestinal stromal tumors with succinate
dehydrogenase complex dysfunction. Future Oncol. 9:121–126. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mussi C, Schildhaus HU, Gronchi A,
Wardelmann E and Hohenberger P: Therapeutic consequences from
molecular biology for gastrointestinal stromal tumor patients
affected by neurofibromatosis type 1. Clin Cancer Res.
14:4550–4555. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chalmers ZR, Connelly CF, Fabrizio D, Gay
L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J,
et al: Analysis of 100,000 human cancer genomes reveals the
landscape of tumor mutational burden. Genome Med. 9:342017.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Feng Y, Yao S, Pu Z, Cheng H, Fei B, Zou J
and Huang Z: Identification of new tumor-related gene mutations in
Chinese gastrointestinal stromal tumors. Front Cell Dev Biol.
9:7642752021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Marabelle A, Fakih M, Lopez J, Shah M,
Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin
JA, Miller WH Jr, et al: Association of tumour mutational burden
with outcomes in patients with advanced solid tumours treated with
pembrolizumab: Prospective biomarker analysis of the multicohort,
open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21:1353–1365.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Patrikidou A, Domont J, Chabaud S,
Ray-Coquard I, Coindre JM, Bui-Nguyen B, Adenis A, Rios M, Bertucci
F, Duffaud F, et al: Long-term outcome of molecular subgroups of
GIST patients treated with standard-dose imatinib in the BFR14
trial of the French sarcoma group. Eur J Cancer. 52:173–180. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Debiec-Rychter M, Dumez H, Judson I, Wasag
B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H,
et al: Use of c-KIT/PDGFRA mutational analysis to predict the
clinical response to imatinib in patients with advanced
gastrointestinal stromal tumours entered on phase I and II studies
of the EORTC soft tissue and bone sarcoma group. Eur J Cancer.
40:689–695. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors: Pathology and prognosis at different sites. Semin
Diagn Pathol. 23:70–83. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Nannini M, Urbini M, Astolfi A, Biasco G
and Pantaleo MA: The progressive fragmentation of the KIT/PDGFRA
wild-type (WT) gastrointestinal stromal tumors (GIST). J Transl
Med. 15:1132017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mavroeidis L, Metaxa-Mariatou V,
Papoudou-Bai A, Lampraki AM, Kostadima L, Tsinokou I, Zarkavelis G,
Papadaki A, Petrakis D, Gκoura S, et al: Comprehensive molecular
screening by next generation sequencing reveals a distinctive
mutational profile of KIT/PDGFRA genes and novel genomic
alterations: Results from a 20-year cohort of patients with GIST
from north-western Greece. ESMO Open. 3:e0003352018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
National Comprehensive Cancer Network
(NCCN), . NCCN guidelines GIST v1.2022. NCCN; Plymouth Meeting, PA:
2022, https://www.nccn.org
|
|
57
|
Vanden Bempt I, Vander Borght S, Sciot R,
Spans L, Claerhout S, Brems H, Lehnert S, Dehaspe L, Fransis S,
Neuville B, et al: Comprehensive targeted next-generation
sequencing approach in the molecular diagnosis of gastrointestinal
stromal tumor. Genes Chromosomes Cancer. 60:239–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Richards S, Aziz N, Bale S, Bick D, Das S,
Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al:
Standards and guidelines for the interpretation of sequence
variants: A joint consensus recommendation of the American college
of medical genetics and genomics and the association for molecular
pathology. Genet Med. 17:405–424. 2015. View Article : Google Scholar : PubMed/NCBI
|
